Synthroid (Levothyroxine) and Pregabalin Interaction: Safety, Timing, and Monitoring

Why This Combination Raises Questions

Patients prescribed levothyroxine for hypothyroidism and pregabalin for neuropathic pain, fibromyalgia, or seizure disorders often worry about drug interactions. That concern makes sense. Levothyroxine has a narrow therapeutic index, and over 60 medications are known to alter its absorption or metabolism. Pregabalin, marketed as Lyrica, belongs to a different pharmacologic class (gabapentinoid anticonvulsant) with a distinct elimination pathway.

The good news: no published evidence or FDA labeling identifies a clinically meaningful pharmacokinetic or pharmacodynamic interaction between these two drugs. The levothyroxine prescribing information lists dozens of interacting agents, including calcium, iron, proton pump inhibitors, and estrogens. Pregabalin does not appear on that list. The pregabalin label similarly reports no interaction with thyroid hormones.

Still, "no listed interaction" is not the same as "no clinical considerations." Two indirect pathways, absorption timing and body-weight changes, deserve attention.

Pharmacokinetic Profiles: No Overlap Where It Matters

Levothyroxine is a synthetic T4 analog absorbed primarily in the jejunum and upper ileum. Its oral bioavailability ranges from 40% to 80% in fasting conditions and falls sharply when the drug is taken with food, calcium, or iron [1]. Levothyroxine undergoes deiodination in peripheral tissues (liver, kidney, muscle) rather than CYP-mediated hepatic metabolism. It is highly protein-bound, primarily to thyroxine-binding globulin (TBG), transthyretin, and albumin [2].

Pregabalin sits at the opposite end of the pharmacokinetic spectrum. It is absorbed rapidly, reaching peak plasma concentration in about 1 hour. Oral bioavailability exceeds 90% regardless of food intake [3]. Pregabalin does not bind to plasma proteins. It undergoes negligible hepatic metabolism, with 98% of the dose excreted unchanged in urine [3]. It does not inhibit or induce CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4. It is not a substrate or inhibitor of P-glycoprotein.

Because the two drugs share no metabolic enzymes, no transporter competition, and no meaningful protein-binding displacement, a conventional pharmacokinetic drug-drug interaction is not expected. The American Thyroid Association (ATA) guidelines on hypothyroidism do not list gabapentinoids among agents requiring levothyroxine dose adjustment.

Absorption Timing Still Matters

The absence of a direct interaction does not eliminate the need for careful timing. Levothyroxine absorption is notoriously sensitive to the gastrointestinal environment. A 2017 systematic review in Thyroid found that co-administration with calcium carbonate reduced levothyroxine absorption by up to 25%, and coffee taken within 30 minutes of dosing reduced it by roughly 30% [4].

Pregabalin is an oral medication typically dosed two or three times daily. Although pregabalin itself has no known chelation or pH-altering properties that would impair levothyroxine absorption, stacking multiple oral medications at the same time creates a practical risk. The ATA recommends taking levothyroxine on an empty stomach, 30 to 60 minutes before breakfast, separated from all other medications [5].

A reasonable clinical approach: take levothyroxine first thing in the morning with a full glass of water, wait at least 30 minutes, then take pregabalin with or without food. Patients who prefer bedtime levothyroxine dosing (a strategy supported by a randomized crossover trial showing improved TSH in some patients) should ensure the last pregabalin dose and the levothyroxine dose are separated by at least 2 hours.

Pregabalin, Weight Gain, and Thyroid Dose Requirements

This is the interaction that textbooks miss. Pregabalin causes dose-dependent weight gain. In the pooled analysis of controlled trials submitted to the FDA, 14% of pregabalin-treated patients gained at least 7% of baseline body weight compared with 2% of placebo-treated patients [3]. Mean weight gain ranged from 1.6 kg at 150 mg/day to 2.0 kg at 600 mg/day over 12 to 14 weeks.

Body weight directly influences levothyroxine dose requirements. The standard full-replacement dose of levothyroxine is approximately 1.6 mcg/kg/day for most adults with primary hypothyroidism [6]. A 5 kg weight gain in a 70 kg patient increases the theoretical requirement by roughly 8 mcg/day. While this may seem small, in a patient already near the upper or lower boundary of their therapeutic window, even modest weight fluctuation can push TSH out of range.

Dr. Victor Bernet, past president of the American Thyroid Association, has noted: "Clinicians should anticipate levothyroxine dose adjustments any time a patient's weight changes by more than 5% to 10%, regardless of the cause" [7]. Pregabalin-induced weight gain falls squarely into this category.

The practical recommendation: recheck TSH 6 to 12 weeks after initiating pregabalin or after any dose escalation. If TSH rises above the patient's target range, increase levothyroxine by 12.5 to 25 mcg and recheck in another 6 weeks. If the patient later discontinues pregabalin and loses weight, reverse the dose adjustment.

CNS Overlap: Sedation Versus Hypothyroid Fatigue

Pregabalin's most common adverse effects include somnolence (affecting 22% of patients at 300 mg/day in fibromyalgia trials) and dizziness (29%). Undertreated hypothyroidism also causes fatigue, cognitive slowing, and depressed mood. When both conditions coexist, distinguishing pregabalin side effects from suboptimal thyroid replacement becomes difficult.

A patient who starts pregabalin and reports increased fatigue may be experiencing drug-induced sedation, rising TSH from weight gain, or both. The ATA guidelines recommend maintaining TSH within the reference range (typically 0.45 to 4.12 mIU/L, with many endocrinologists targeting 0.5 to 2.5 mIU/L for symptomatic patients) [5]. Confirming TSH is on target before attributing all fatigue to pregabalin prevents missed dose adjustments.

Dr. Elizabeth Pearce, an endocrinologist at Boston Medical Center and former ATA secretary, has stated: "Any new symptom that overlaps with hypothyroid complaints, especially fatigue and weight gain, should trigger a TSH recheck before assuming the thyroid is adequately treated" [8].

What the Major Drug Interaction Databases Say

Three widely used clinical decision-support tools, Lexicomp, Micromedex, and Clinical Pharmacology, do not flag a levothyroxine-pregabalin interaction. A search of the FDA Adverse Event Reporting System (FAERS) database for reports listing both levothyroxine and pregabalin does not reveal a signal for a pharmacokinetic interaction.

The UpToDate drug interaction tool, referenced widely in clinical pharmacy practice, returns "no known interaction" for this pair as of 2025. The absence of a signal across multiple independent databases, combined with the non-overlapping pharmacokinetic profiles described above, provides strong reassurance.

This does not mean the combination is free of all considerations. It means the considerations are clinical management issues (timing, weight monitoring, symptom overlap) rather than molecular drug-drug interactions.

Who Needs Extra Vigilance

Certain patient groups warrant closer monitoring when taking both medications.

Post-thyroidectomy patients rely entirely on exogenous levothyroxine with no residual endogenous production. Even small absorption disruptions or dose-requirement shifts from weight change can cause symptomatic hypothyroidism or suppress TSH below target [9].

Elderly patients (age 65 and older) are more sensitive to both pregabalin-related CNS depression and levothyroxine dose changes. The American Geriatrics Society Beers Criteria lists pregabalin as a medication to use with caution in older adults due to fall risk from dizziness and somnolence. A TSH target of 0.5 to 3.0 mIU/L is reasonable in this population to avoid over-replacement [10].

Patients with renal impairment require pregabalin dose reduction (the FDA label recommends a maximum of 300 mg/day at creatinine clearance 30 to 60 mL/min and 150 mg/day at creatinine clearance 15 to 30 mL/min [3]). Levothyroxine dosing is not renally adjusted, but chronic kidney disease itself alters thyroid hormone binding and free T4 measurement accuracy [11].

Patients on narrow-therapeutic-index levothyroxine formulations such as Tirosint (gel cap) or Tirosint-SOL (liquid) may see less absorption variability from co-administered medications compared with standard tablets. For patients who struggle with consistent absorption, switching to a liquid or gel-cap formulation can reduce variability by up to 30% [12].

Practical Dosing Protocol

A step-by-step approach for clinicians managing a patient on both agents:

1. Baseline TSH and free T4 before starting pregabalin. Confirm levothyroxine dose is optimized.
2. Counsel on timing: levothyroxine 30 to 60 minutes before the first pregabalin dose of the day, taken with water only.
3. Recheck TSH at 6 to 12 weeks after pregabalin initiation or dose change.
4. Monitor weight at each visit. If weight increases by more than 5%, anticipate the need for a levothyroxine dose increase of 12.5 to 25 mcg.
5. Assess for symptom overlap: fatigue, cognitive slowing, and mood changes. Do not attribute these solely to pregabalin without confirming TSH is within target.
6. If pregabalin is discontinued, recheck TSH in 6 to 8 weeks and consider a levothyroxine dose reduction if weight decreases.

Patients taking calcium, iron, or antacids should separate those agents from levothyroxine by at least 4 hours, a more stringent interval than the 30-minute pregabalin separation, because chelation-mediated absorption loss is a distinct and well-documented mechanism [1].